People: Quest Diagnostics Inc (DGX.N)

DGX.N on New York Stock Exchange

18 Apr 2019
Change (% chg)

$0.05 (+0.06%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Leiden, Jeffrey 

Dr. Jeffrey M. Leiden, M.D. Ph.D. is no longer Independent Director of the Company, effective May 14, 2019. Dr. Leiden has been Chairman, President and CEO of Vertex Pharmaceuticals Incorporated since 2011. He has served as a member of Vertex’s board of directors since 2009. Prior to joining Vertex in 2011, Dr. Leiden was a Managing Director at Clarus Ventures, a life sciences venture capital firm he joined in 2006. From 2000 to 2006, he served as President and Chief Operating Officer and Chief Scientific Officer at Abbott Laboratories, where he had responsibility for managing all aspects of Abbott’s global pharmaceutical business. Previously, Dr. Leiden held several academic and hospital appointments, including as Chief of Cardiology at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School. He has extensive consulting experience in the pharmaceutical and medical device areas. Dr. Leiden served as a director of Abbott Laboratories from 2001 to 2006, Shire Pharmaceuticals plc from 2007 to 2011 and Millennium Pharmaceuticals, Inc. from 2008 to 2009. He is a fellow of the American Academy of Arts and Sciences, and an elected member of the Institute of Medicine of the National Academy of Sciences.

Basic Compensation

Total Annual Compensation, USD 113,000
Restricted Stock Award, USD 167,965
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 280,965

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Stephen Rusckowski


Mark Guinan


James Davis


Gabrielle Wolfson


Michael Prevoznik


Jon Cohen

As Of  31 Dec 2017